Complete report details @https://www.wiseguyreports.com/reports/649773-wet-neovascular-exudative-macular-degeneration-pipeline-review-h2-2016
Summary
‘Wet (Neovascular /
Exudative) Macular Degeneration - Pipeline Review, H2 2016’, provides an
overview of the Wet (Neovascular / Exudative) Macular Degeneration pipeline
landscape.
The report provides comprehensive information on the
therapeutics under development for Wet (Neovascular / Exudative) Macular
Degeneration, complete with analysis by stage of development, drug target, mechanism
of action (MoA), route of administration (RoA) and molecule type. The report
also covers the descriptive pharmacological action of the therapeutics, its
complete research and development history and latest news and press releases.
Additionally, the report provides an overview of key players involved in
therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration
and features dormant and discontinued projects.
Report features investigational drugs from across globe
covering over 20 therapy areas and nearly 3,000 indications. The report is
built using data and information sourced from proprietary databases,
company/university websites, clinical trial registries, conferences, SEC
filings, investor presentations and featured press releases from
company/university sites and industry-specific third party sources. Drug
profiles featured in the report undergoes periodic review following a stringent
set of processes to ensure that all the profiles are updated with the latest
set of information. Additionally, various dynamic tracking processes ensure
that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging
players in the market and their portfolios, enhances decision making capabilities
and helps to create effective counter strategies to gain competitive advantage.
Request a sample report @ https://www.wiseguyreports.com/sample-request/649773-wet-neovascular-exudative-macular-degeneration-pipeline-review-h2-2016
Scope
- The report provides a snapshot of the global therapeutic
landscape of Wet (Neovascular / Exudative) Macular Degeneration
- The report reviews pipeline therapeutics for Wet (Neovascular / Exudative) Macular Degeneration by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Wet (Neovascular / Exudative) Macular Degeneration therapeutics and enlists all their major and minor projects
- The report assesses Wet (Neovascular / Exudative) Macular Degeneration therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Wet (Neovascular / Exudative) Macular Degeneration
- The report reviews pipeline therapeutics for Wet (Neovascular / Exudative) Macular Degeneration by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Wet (Neovascular / Exudative) Macular Degeneration therapeutics and enlists all their major and minor projects
- The report assesses Wet (Neovascular / Exudative) Macular Degeneration therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Wet (Neovascular / Exudative) Macular Degeneration
Reasons to buy
- Gain strategically significant competitor information,
analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Wet (Neovascular / Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Wet (Neovascular / Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Make an enquiry before buying this Report @
https://www.wiseguyreports.com/enquiry/649773-wet-neovascular-exudative-macular-degeneration-pipeline-review-h2-2016
Table of
Contents
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Wet (Neovascular / Exudative) Macular Degeneration Overview 10
Therapeutics Development 11
Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Overview 11
Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Development by Companies 12
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Wet (Neovascular / Exudative) Macular Degeneration - Products under Development by Companies 19
Wet (Neovascular / Exudative) Macular Degeneration - Companies Involved in Therapeutics Development 25
Aciont Inc. 25
Adverum Biotechnologies, Inc. 26
Allergan Plc 27
Alteogen Inc. 28
Amakem NV 29
Ampio Pharmaceuticals, Inc. 30
Apellis Pharmaceuticals, Inc. 31
Apexigen, Inc. 32
Applied Genetic Technologies Corporation 33
Benitec Biopharma Limited 34
Boehringer Ingelheim GmbH 35
Cell Medica Limited 36
Charlesson LLC. 37
Cipla Ltd. 38
Clanotech AB 39
Clearside BioMedical, Inc. 40
Clonz Biotech Private Limited 41
Coherus BioSciences, Inc. 42
Daiichi Sankyo Company, Limited 43
Diffusion Pharmaceuticals Inc. 44
Eleven Biotherapeutics Inc. 45
Exonate Limited 46
F. Hoffmann-La Roche Ltd. 47
Formycon AG 48
Graybug Vision Inc 49
GTx, Inc. 50
iCo Therapeutics Inc. 51
Icon Bioscience, Inc. 52
Iconic Therapeutics, Inc. 53
Kala Pharmaceuticals, Inc. 54
Kodiak Sciences Inc. 55
Mabion SA 56
MeiraGTx Limited 57
Mitotech S.A. 58
Ocular Therapeutix, Inc. 59
Ohr Pharmaceutical Inc. 60
Ophthotech Corp. 61
Oxford BioMedica Plc 62
PanOptica, Inc. 63
Pfenex Inc. 64
Pfizer Inc. 65
pSivida Corp. 66
Regeneron Pharmaceuticals Inc 67
RegenxBio Inc. 68
RXi Pharmaceuticals Corporation 69
Santen Pharmaceutical Co., Ltd. 70
Sanwa Kagaku Kenkyusho Co., Ltd. 71
TRACON Pharmaceuticals, Inc. 72
TWi Pharmaceuticals, Inc. 73
Tyrogenex, Inc. 74
Xbrane Biopharma AB 75
Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics Assessment 76
Assessment by Monotherapy Products 76
Assessment by Combination Products 77
Assessment by Target 78
Assessment by Mechanism of Action 81
Assessment by Route of Administration 85
Assessment by Molecule Type 87
Drug Profiles 89
(aflibercept + nesvacumab) - Drug Profile 89
(aflibercept + rinucumab) - Drug Profile 90
A-006 - Drug Profile 91
abicipar pegol - Drug Profile 92
AC-301 - Drug Profile 95
ACX-107 - Drug Profile 96
aflibercept - Drug Profile 97
aflibercept biosimilar - Drug Profile 106
aflibercept biosimilar - Drug Profile 107
AGN-151200 - Drug Profile 108
ALG-1001 - Drug Profile 110
AMA-0428 - Drug Profile 113
APL-2 - Drug Profile 114
APX-003 - Drug Profile 116
APX-3330 - Drug Profile 117
AVA-101 - Drug Profile 119
AVA-201 - Drug Profile 122
avacincaptad pegol sodium - Drug Profile 123
axitinib - Drug Profile 125
AXT-108 - Drug Profile 127
bertilimumab - Drug Profile 128
Beta-LGND2 - Drug Profile 132
BI-144807 - Drug Profile 134
brolucizumab - Drug Profile 135
C-16Y - Drug Profile 137
CBT-128 - Drug Profile 138
CLT-005 - Drug Profile 139
CLT-28643 - Drug Profile 140
cyclosporine - Drug Profile 141
DA-3131 - Drug Profile 142
danazol - Drug Profile 143
DE-120 - Drug Profile 147
DNX-214 - Drug Profile 148
Doxarubicin Pegylated - Drug Profile 149
Drug for Age Related Macular Degeneration - Drug Profile 150
DS-7080 - Drug Profile 151
ENV-1305 - Drug Profile 152
GB-101 - Drug Profile 153
Gene Therapy 1 for Wet Age-Related Macular Degeneration - Drug Profile 154
Gene Therapy for Wet Age-related Macular Degeneration - Drug Profile 155
hI-con1 - Drug Profile 156
IVMED-50 - Drug Profile 158
IVMED-55 - Drug Profile 159
K-106 - Drug Profile 160
KSI-201 - Drug Profile 161
LHA-510 - Drug Profile 162
Monoclonal Antibody to Inhibit VEGF for Wet Age Related Macular Degeneration - Drug Profile 163
OCU-200 - Drug Profile 164
OLX-301 - Drug Profile 165
ONL-1204 - Drug Profile 166
OPT-302 - Drug Profile 167
OXB-201 - Drug Profile 171
PAN-90806 - Drug Profile 173
pegpleranib sodium - Drug Profile 175
PF-05206388 - Drug Profile 178
PF-655 - Drug Profile 180
plastoquinone decyl triphenylphosphonium bromide - Drug Profile 182
Protein to Inhibit VEGF for Wet Age Related Macular Degeneration - Drug Profile 184
ranibizumab - Drug Profile 185
ranibizumab biosimilar - Drug Profile 191
ranibizumab biosimilar - Drug Profile 192
ranibizumab biosimilar - Drug Profile 193
ranibizumab biosimilar - Drug Profile 195
ranibizumab biosimilar - Drug Profile 196
ranibizumab biosimilar - Drug Profile 197
ranibizumab biosimilar - Drug Profile 198
Recombinant Protein for Age Related Macular Degeneration - Drug Profile 199
Recombinant Proteins to Inhibit VEGF for Wet Age Related Macular Degeneration - Drug Profile 200
RES-529 - Drug Profile 201
RG-7716 - Drug Profile 205
RGX-314 - Drug Profile 206
RXI-109 - Drug Profile 208
SK-1011 - Drug Profile 214
Small Molecule for Wet AMD and Dry AMD - Drug Profile 215
Small Molecules for Dry and Wet Age Related Macular Degeneration - Drug Profile 216
Small Molecules to Inhibit SRPK-1 for Wet Macular Degeneration - Drug Profile 217
SPHINX-31 - Drug Profile 218
squalamine lactate - Drug Profile 219
sunitinib malate - Drug Profile 227
Synthetic Peptides to Inhibit VEGF for Wet Adult Macular Degeneration - Drug Profile 229
TRC-105 - Drug Profile 230
triamcinolone acetonide - Drug Profile 238
TT-211 - Drug Profile 239
TT-231 - Drug Profile 240
X-82 - Drug Profile 241
Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects 244
Wet (Neovascular / Exudative) Macular Degeneration - Discontinued Products 248
Wet (Neovascular / Exudative) Macular Degeneration - Product Development Milestones 249
Featured News & Press Releases 249
Appendix 259
Methodology 259
Coverage 259
Secondary Research 259
Primary Research 259
Expert Panel Validation 259
Contact Us 259
Disclaimer 260
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Wet (Neovascular / Exudative) Macular Degeneration Overview 10
Therapeutics Development 11
Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Overview 11
Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Development by Companies 12
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Wet (Neovascular / Exudative) Macular Degeneration - Products under Development by Companies 19
Wet (Neovascular / Exudative) Macular Degeneration - Companies Involved in Therapeutics Development 25
Aciont Inc. 25
Adverum Biotechnologies, Inc. 26
Allergan Plc 27
Alteogen Inc. 28
Amakem NV 29
Ampio Pharmaceuticals, Inc. 30
Apellis Pharmaceuticals, Inc. 31
Apexigen, Inc. 32
Applied Genetic Technologies Corporation 33
Benitec Biopharma Limited 34
Boehringer Ingelheim GmbH 35
Cell Medica Limited 36
Charlesson LLC. 37
Cipla Ltd. 38
Clanotech AB 39
Clearside BioMedical, Inc. 40
Clonz Biotech Private Limited 41
Coherus BioSciences, Inc. 42
Daiichi Sankyo Company, Limited 43
Diffusion Pharmaceuticals Inc. 44
Eleven Biotherapeutics Inc. 45
Exonate Limited 46
F. Hoffmann-La Roche Ltd. 47
Formycon AG 48
Graybug Vision Inc 49
GTx, Inc. 50
iCo Therapeutics Inc. 51
Icon Bioscience, Inc. 52
Iconic Therapeutics, Inc. 53
Kala Pharmaceuticals, Inc. 54
Kodiak Sciences Inc. 55
Mabion SA 56
MeiraGTx Limited 57
Mitotech S.A. 58
Ocular Therapeutix, Inc. 59
Ohr Pharmaceutical Inc. 60
Ophthotech Corp. 61
Oxford BioMedica Plc 62
PanOptica, Inc. 63
Pfenex Inc. 64
Pfizer Inc. 65
pSivida Corp. 66
Regeneron Pharmaceuticals Inc 67
RegenxBio Inc. 68
RXi Pharmaceuticals Corporation 69
Santen Pharmaceutical Co., Ltd. 70
Sanwa Kagaku Kenkyusho Co., Ltd. 71
TRACON Pharmaceuticals, Inc. 72
TWi Pharmaceuticals, Inc. 73
Tyrogenex, Inc. 74
Xbrane Biopharma AB 75
Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics Assessment 76
Assessment by Monotherapy Products 76
Assessment by Combination Products 77
Assessment by Target 78
Assessment by Mechanism of Action 81
Assessment by Route of Administration 85
Assessment by Molecule Type 87
Drug Profiles 89
(aflibercept + nesvacumab) - Drug Profile 89
(aflibercept + rinucumab) - Drug Profile 90
A-006 - Drug Profile 91
abicipar pegol - Drug Profile 92
AC-301 - Drug Profile 95
ACX-107 - Drug Profile 96
aflibercept - Drug Profile 97
aflibercept biosimilar - Drug Profile 106
aflibercept biosimilar - Drug Profile 107
AGN-151200 - Drug Profile 108
ALG-1001 - Drug Profile 110
AMA-0428 - Drug Profile 113
APL-2 - Drug Profile 114
APX-003 - Drug Profile 116
APX-3330 - Drug Profile 117
AVA-101 - Drug Profile 119
AVA-201 - Drug Profile 122
avacincaptad pegol sodium - Drug Profile 123
axitinib - Drug Profile 125
AXT-108 - Drug Profile 127
bertilimumab - Drug Profile 128
Beta-LGND2 - Drug Profile 132
BI-144807 - Drug Profile 134
brolucizumab - Drug Profile 135
C-16Y - Drug Profile 137
CBT-128 - Drug Profile 138
CLT-005 - Drug Profile 139
CLT-28643 - Drug Profile 140
cyclosporine - Drug Profile 141
DA-3131 - Drug Profile 142
danazol - Drug Profile 143
DE-120 - Drug Profile 147
DNX-214 - Drug Profile 148
Doxarubicin Pegylated - Drug Profile 149
Drug for Age Related Macular Degeneration - Drug Profile 150
DS-7080 - Drug Profile 151
ENV-1305 - Drug Profile 152
GB-101 - Drug Profile 153
Gene Therapy 1 for Wet Age-Related Macular Degeneration - Drug Profile 154
Gene Therapy for Wet Age-related Macular Degeneration - Drug Profile 155
hI-con1 - Drug Profile 156
IVMED-50 - Drug Profile 158
IVMED-55 - Drug Profile 159
K-106 - Drug Profile 160
KSI-201 - Drug Profile 161
LHA-510 - Drug Profile 162
Monoclonal Antibody to Inhibit VEGF for Wet Age Related Macular Degeneration - Drug Profile 163
OCU-200 - Drug Profile 164
OLX-301 - Drug Profile 165
ONL-1204 - Drug Profile 166
OPT-302 - Drug Profile 167
OXB-201 - Drug Profile 171
PAN-90806 - Drug Profile 173
pegpleranib sodium - Drug Profile 175
PF-05206388 - Drug Profile 178
PF-655 - Drug Profile 180
plastoquinone decyl triphenylphosphonium bromide - Drug Profile 182
Protein to Inhibit VEGF for Wet Age Related Macular Degeneration - Drug Profile 184
ranibizumab - Drug Profile 185
ranibizumab biosimilar - Drug Profile 191
ranibizumab biosimilar - Drug Profile 192
ranibizumab biosimilar - Drug Profile 193
ranibizumab biosimilar - Drug Profile 195
ranibizumab biosimilar - Drug Profile 196
ranibizumab biosimilar - Drug Profile 197
ranibizumab biosimilar - Drug Profile 198
Recombinant Protein for Age Related Macular Degeneration - Drug Profile 199
Recombinant Proteins to Inhibit VEGF for Wet Age Related Macular Degeneration - Drug Profile 200
RES-529 - Drug Profile 201
RG-7716 - Drug Profile 205
RGX-314 - Drug Profile 206
RXI-109 - Drug Profile 208
SK-1011 - Drug Profile 214
Small Molecule for Wet AMD and Dry AMD - Drug Profile 215
Small Molecules for Dry and Wet Age Related Macular Degeneration - Drug Profile 216
Small Molecules to Inhibit SRPK-1 for Wet Macular Degeneration - Drug Profile 217
SPHINX-31 - Drug Profile 218
squalamine lactate - Drug Profile 219
sunitinib malate - Drug Profile 227
Synthetic Peptides to Inhibit VEGF for Wet Adult Macular Degeneration - Drug Profile 229
TRC-105 - Drug Profile 230
triamcinolone acetonide - Drug Profile 238
TT-211 - Drug Profile 239
TT-231 - Drug Profile 240
X-82 - Drug Profile 241
Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects 244
Wet (Neovascular / Exudative) Macular Degeneration - Discontinued Products 248
Wet (Neovascular / Exudative) Macular Degeneration - Product Development Milestones 249
Featured News & Press Releases 249
Appendix 259
Methodology 259
Coverage 259
Secondary Research 259
Primary Research 259
Expert Panel Validation 259
Contact Us 259
Disclaimer 260
Contact US:
NORAH TRENT
Partner Relations
& Marketing Manager
sales@wiseguyreports.com
Ph:
+1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
No comments:
Post a Comment